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Membersof the interleukin-1 (IL-1) family of cytokines
play major roles in host defense and immune system
regulation in infectious and inflammatory diseases.
IL-1 cytokines trigger a biological response in
effector cells by assembling a heterotrimeric sig-
naling complex with two IL-1 receptor chains, a
high-affinity primary receptor and a low-affinity core-
ceptor. To gain insights into the signalingmechanism
of the novel IL-1-like cytokine IL-33, we first solved its
solution structure and then performed a detailed
biochemical and structural characterization of the
interaction between IL-33, its primary receptor ST2,
and the coreceptor IL-1RAcP. Using nuclear mag-
netic resonance data, we obtained a model of the
IL-33/ST2 complex in solution that is validated by
small-angle X-ray scattering (SAXS) data and is
similar to the IL-1b/IL-1R1 complex. We extended
our SAXS analysis to the IL-33/ST2/IL-1RAcP and
IL-1b/IL-1R1/IL-1RAcP complexes and propose a
general model of the molecular architecture of IL-1
ternary signaling complexes.
INTRODUCTION
The interleukin-1 (IL-1) family of immune regulatory cytokines in
humans comprises a group of eleven secreted factors that
include IL-1a, IL-1b, IL-18, and, the most recent addition, IL-33
(for review, see Arend et al., 2008; Barksby et al., 2007; Dinarello,
2009). Several members of this cytokine family exhibit an uncon-
ventional secretion mechanism with their initial synthesis as
leaderless precursors in the cytosol, and then activation by a cas-
pase-1-mediated proteolytic cleavage of their N-terminal prodo-
mains (IL-1b, IL-18, and IL-1F7; Keller et al., 2008; Sharma et al.,
2008). Unexpectedly, proIL-33 does not need to be matured by
caspase-1 for secretion and bioactivity (Lamkanfi and Dixit,
2009). Themature forms of these cytokines have a single b-trefoil
domain that is shared with fibroblast growth factors (FGFs)
(Ponting and Russell, 2000) and bind to signaling receptors of
the IL-1 receptor family on their target cells. This class of recep-1398 Structure 17, 1398–1410, October 14, 2009 ª2009 Elsevier Ltdtors typically possess three extracellular immunoglobulin (Ig)-like
repeats and belong to the greater Toll-IL-1 receptor (TIR) super-
family by virtue of their intracellular signaling domain, a distinctive
TIR module (Boraschi and Tagliabue, 2006; O’Neill, 2008). IL-1
cytokine binding drives the assembly of a heterodimer of IL-1
receptor chains, forming a ternary signaling complex with paired
TIR domains. These recruit MyD88 and other cytosolic adaptor
proteins leading ultimately to the activation of NF-kB and trig-
gering of the proinflammatory response (Boraschi and Taglia-
bue, 2006; O’Neill, 2008).
A critical trio of proinflammatory cytokines, IL-1a, IL-1b, and
IL-18, can cause severe pathologic effects if their sustained
production or signaling is not carefully regulated (Arend et al.,
2008;Barksby et al., 2007;Dinarello, 2009). To this effect, a series
of natural antagonists block the ordered assembly of selected
IL-1 signaling complexes, revealing insights into themechanisms
of IL-1 receptor binding (Feldmann, 2008). IL-1 receptor antago-
nist (IL-1Ra) competes with IL-1a and IL-1b for binding to their
primary receptor, the IL-1 receptor type 1 (IL-1R1). This IL-1Ra/
IL-1R1 complex does not form a productive ternary complexwith
the coreceptor, the IL-1 receptor accessory protein (IL-1RAcP)
(Arend et al., 2008; Barksby et al., 2007; Evans et al., 1995). In
contrast, the IL-1 receptor type 2 (IL-1R2), which lacks an intra-
cellular TIR domain, acts as a decoy receptor by competing
with IL-1R1 for IL-1a and IL-1b binding. The IL-18 binding protein
(IL-18BP) in turn comprises a secreted, single Ig domain sink for
IL-18 (Arend et al., 2008; Barksby et al., 2007).
IL-33 is the ligand of the ST2 orphan IL-1 receptor (also known
as T1, FIT-1, or DER4) (Dinarello, 2005; Schmitz et al., 2005). The
signaling form of ST2 (or ST2L, the ‘‘long’’ transmembrane
variant) is principally expressed in T helper cell type 2 (Th2)
and mast cells (Lohning et al., 1998; Trajkovic et al., 2004).
Accordingly, IL-33 has been shown to be involved in Th2-medi-
ated immune responses, such as asthma, allergy-induced
inflammation, and parasitic infections, and potently stimulates
mast cells, basophils, and eosinophils (Kakkar and Lee, 2008;
Saenz et al., 2008; Schmitz et al., 2005). Gene loci for both
ST2 and IL-33 have been flagged by genome-wide association
scans using single nucleotide polymorphism arrays as linked to
asthma, a Th2 immune disorder (Gudbjartsson et al., 2009).
Intriguingly, the coreceptor for IL-33, IL-1RAcP, is promiscu-
ously shared with the IL-1a/b signaling complex (Ali et al.,
2007; Chackerian et al., 2007; Palmer et al., 2008).All rights reserved
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1990), IL-1b (Priestle et al., 1989), IL-1Ra (Vigers et al., 1994),
IL-18 (Kato et al., 2003), and IL-1F5 (Dunn et al., 2003) share
a core b-trefoil fold comprised of 12 b strands arranged in
a distinctive three-fold symmetric pattern. How this cytokine
fold engages its specific cellular receptors is only partly dis-
closed by the respective crystal structures of agonist IL-1b and
antagonist IL-1Ra bound to the ectodomain of IL-1R1
(Schreuder et al., 1997; Vigers et al., 1997). Both complexes
show a common Ig-repeat architecture for the IL-1R1 ectodo-
main (modules D1 andD2 tightly interacting and linked by a disul-
fide bond, separated from D3 by an extended eight residue
linker) and differ only in the nature of the contacts with the bound
cytokine. The loss of a critical D3 interaction by IL-1Ra (with
respect to bound IL-1b) is the likely structural basis for antago-
nism (Schreuder et al., 1997). In contrast, another antagonist
relies exclusively on themaintenance of this D3-cytokine contact
for biological activity, as demonstrated by the structure of
a poxvirus homolog of IL-18BP, a single D3-like Ig domain,
bound to human IL-18 (Krummet al., 2008). The relative indepen-
dence of the D1-D2 Ig bloc from the D3 segment was evident in
a complex of IL-1R1 with a short antagonistic peptide where D3
rotates by almost 180 to trap the peptide against the concave
surface of D1-D2 (Vigers et al., 2000). This suggests that
IL-1R1 and the extended family of IL-1 receptors can show
significant conformational variability in the unbound state and
adopt multiple bound structures.
The pose captured by the archetypal complex of IL-1b with
IL-1R1 (Vigers et al., 1997) lacks the additional signaling chain
required for bioactivity. The architecture of the full IL-1 ternary
receptor complex remains elusive, though the expectation has
been that a pseudosymmetric arrangement would provide the
best model (Stroud and Wells, 2004; Wiesmann and de Vos,
2000). However, though the distantly related FGF b-trefoil
cytokines bind to their Ig-repeat FGF receptor (FGFR) ectodo-
mains in a similar fashion to IL-1b, the active FGFR assembly is
a back-to-back receptor pair with outwardly mounted FGF
ligands tied together by a heparan sulfate chain (Mohammadi
et al., 2005).Heparin is not a requirement for IL-1 cytokinebinding
and, furthermore, the suggested 1:1:1 stoichiometry of primary
receptor to coreceptor to IL-1 ligand is distinct from the FGF
system (Boraschi and Tagliabue, 2006). With FGFs as an unreli-
able guide, one attempt to sort through IL-1 alternatives invoked
the in silico docking of a molecular model of the coreceptor
IL-1RAcP onto the existing IL-1b/IL-1R1 structure (Casadio
et al., 2001). This resulted in two distinct configurations: in the
‘‘front’’model, the IL-1RAcPchain approaches the IL-1R1-bound
IL-1b from the solvent-exposed face, while in the ‘‘back’’ model,
IL-1RAcP is placed on theopposite side of the engaged IL-1R1. A
key experiment designed to distinguish between these different
models used antibodies raised against an exposed loop of
IL-1b; these antibodies do not impede IL-1RAcP ternary interac-
tion, suggesting that the front model is incorrect. This prediction
clearly sets the IL-1 signaling architecture on a different course
from other paradigmatic receptor complexes that are nucleated
around a centrally placed cytokine ligand (Stroud and Wells,
2004;Wang et al., 2009;Wiesmann and deVos, 2000). To resolve
this issue of the molecular arrangement of IL-1 family heterotri-
meric signaling complexes, in the present study we demonstrateStructure 17, 1398–the IL-1-like b-trefoil fold of the IL-33 cytokine by nuclear
magnetic resonance (NMR) spectroscopy and characterize its
sequential assembly with ST2 and IL-1RAcP receptor chains by
biochemical methods, NMR, and X-ray solution studies. To
show that we define a consistent model for the greater IL-1
system, we use a parallel structural study of IL-1b, IL-1R1, and
IL-1RAcP molecules to draw a unified ternary architecture for
IL-1 cytokine signaling.
RESULTS
Solution Structure of Human IL-33
The IL-1-like fold of mature IL-33 was recognized by a sensitive
computational screen using sequence profiles based on the
structural alignment of IL-1 and FGF b-trefoil cytokines (at
a low identity level, 16% over 139 residues aligned with human
IL-1b). To confirm the fold prediction, we have solved the solu-
tion structure of recombinant human IL-33 by multidimensional
heteronuclear NMR spectroscopy (Figures 1A and 1B and
Table 1). IL-33 indeed adopts a b-trefoil fold similar to that
described for IL-1a, IL-1b, IL-1Ra, and IL-18 (Figure 1B). In brief,
the 12 b strands of the b-trefoil (numbered b1–b12) are arrayed in
three pseudorepeats of four b strand units, of which the first and
last b strands are antiparallel staves in a six stranded b barrel,
while the second and third b strands of each repeat form a b hair-
pin sitting atop the b barrel. Two short helices (a1 and a2) in IL-33
precede strands b8 and b12 and are located at equivalent posi-
tions to analogous helices in IL-1b and IL-18, respectively.
Superposition by SSM (Krissinel and Henrick, 2004) of the lowest
energy model of IL-33 with other IL-1 cytokine folds shows that
the b-trefoil core is well conserved while differences apportion to
the loops. In particular, the b4-b5 linker in IL-33 has a 10 amino
acid loop insertion relative to other IL-1 cytokines (see
Figure S1 available online); this loop is flexible and unstructured
in solution as evidenced by low {1H}-15N heteronuclear NOE
values (Figure 1C) and the lack of any long-range NOEs. Other
regions of the protein with increased backbone dynamics (heter-
onuclear NOE values <0.6) are the N terminus (residues 1–9), the
b3-b4 loop (residues 40–46), the b11-b12 loop (residues 143–
150), and the C-terminal tail (residues 159 and 160).
Biochemical Interaction of IL-33 with ST2 and IL-1RAcP
The primary, high-affinity receptor for IL-33 is the IL-1 receptor
family member ST2. The IL-33/ST2 complex has been shown
to use the same coreceptor as the IL-1b/IL-1R1 system, namely
IL-1RAcP (Ali et al., 2007; Chackerian et al., 2007; Palmer et al.,
2008). To characterize these interactions in solution, the ectodo-
mains of ST2 and IL-1RAcP were produced by insect cells using
the baculovirus expression system. Both receptor chains were
secreted into the medium and purified to homogeneity in milli-
gram quantities (Figure S2). To test whether the proteins were
folded, we performed an initial binding analysis by size exclusion
chromatography. The mixture of IL-33 and ST2 showed
a decreased retention volume compared to ST2 alone, indicating
complex formation between IL-33 and ST2 (Figures 2A and 2B).
There was an additional shift toward higher molecular weight
when all three proteins were combined, indicating ternary
complex formation. However, addition of the IL-1RAcP corecep-
tor to either IL-33 or ST2 did not result in a change of the elution1410, October 14, 2009 ª2009 Elsevier Ltd All rights reserved 1399
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Heterotrimeric IL-1 Signaling ComplexesFigure 1. Solution Structure and Backbone Dynamics of IL-33
(A) Stereo view of the IL-33 ensemble. The ensemble of the ten lowest-energy NMR structures is shown. Helices are shown in blue and b strands in green.
Secondary structure elements are labeled by residue numbers (numbering is based on the proposed caspase-1 cleavage site).
(B) Ribbon representation of IL-33. Secondary structure elements are labeled.
(C) Additional NMR data on IL-33. The secondary structure is shown above the sequence. Solvent-protected amide protons (slow H/D exchange in NMR
measurements) are indicated by filled circles. Heteronuclear {1H}-15N NOE data (black bars) report regions of IL-33 that are rigid and regions of increased back-
bone dynamics.profile of the individual proteins. Lack of binding of IL-1RAcP to
IL-33 with even low affinity was further confirmed by an NMR
experiment in which IL-1RAcP was added to IL-33 without any
observable spectral changes (data not shown). We conclude
that binding of IL-1RAcP coreceptor requires the initial complex
formation between IL-33 and ST2 and furthermore does not
engage either of the proteins alone. Two reasons could explain
this observation: the binding site for the coreceptor is
a composite surface with contributions from both IL-33 and
ST2 and/or binding of the coreceptor requires a conformational
shift in the ST2 primary receptor. Significant structural variation
in IL-33 is unlikely, since IL-1b, IL-1Ra, and IL-18 experience
only minor changes upon binding to IL-1R1 and IL-18BP,
respectively (Krumm et al., 2008; Schreuder et al., 1997; Vigers
et al., 1997).
To gain a quantitative measure of the binding events during
the formation of the ternary complex, we performed isothermal
titration calorimetry experiments. ST2 binds IL-33 with a dissoci-
ation constant of 4 nM and a stoichiometry of 1:1 (Figure 2C).
Analysis of the thermodynamic contributions to complex forma-
tion reveals that the binding interaction is largely driven by
enthalpy (DH46 kcal/mol). In agreement, themapped binding
interface between IL-33 and ST2 is mainly polar (see below). The
large enthalpy compensates the considerable, unfavorable neg-
ative entropic term of the binding reaction (TDS34 kcal/mol).1400 Structure 17, 1398–1410, October 14, 2009 ª2009 Elsevier LtdThis can be rationalized by a conformational change that the ST2
receptor has to undergo when binding to the cytokine. Although
there are no structural data on unbound forms of any of the IL-1
receptors, it is highly likely that the linker between the D1-D2 Ig
bloc and D3 is flexible and allows multiple ectodomain confor-
mations (as discussed above). The negative entropy of the
binding reaction can therefore be explained by the constraining
of the conformational variability of ST2 on forming the cytokine
complex.
The IL-33/ST2 complex in turn binds IL-1RAcP with a KD of
76 nM and a stoichiometry of 1:1:1 (Figure 2C). The interaction
has a negative binding enthalpy as well (DH 11 kcal/mol),
although it is significantly smaller than that released during
the binding of ST2 to IL-33. The reduction of entropy is small
(TDS 1 kcal/mol), suggesting that any conformational fixing
of the coreceptor upon assembly is compensated in large part
by the release of water molecules from a hydrophobic area
that is part of the binding interface. The interaction between
the IL-33/ST2 complex and IL-1RAcP is therefore likely charac-
terized by a combination of polar and nonpolar contacts.
Chemical Shift Mapping of the Interaction
of IL-33 with ST2
Addition of ST2 to IL-33 results in a large number of chemical
shift perturbations suggesting an extensive interface betweenAll rights reserved
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Heterotrimeric IL-1 Signaling ComplexesTable 1. Structural Statistics for the Solution Structure of IL-33
hSAia hSAiwater refineda
Number of structural
restraints
NOE-derived distance
restraints
Total (unambiguous/
ambiguous)
4693 (4661/32)
Intraresidual 1714 (1712/2)
Sequential 909 (898/11)
Medium range 423 (419/4)
Long range 1647 (1632/15)
Dihedral restraints 245
f 123
c 122
Hydrogen bondsb 76
Violations
Rmsd from experimental
restraints
NOE distance restraints (A˚) 0.0055 ± 0.0006 0.0115 ± 0.0018
Dihedral restraints () 0.15 ± 0.02 0.43 ± 0.05
NOE distance violations
Number > 0.1 A˚ 1.9 ± 0.9 13.6 ± 3.2
Number > 0.3 A˚ 0 0.7 ± 1.0
Dihedral violations
Number > 1 1.3 ± 0.9 13.7 ± 2.8
Number > 2 0 3.2 ± 1.3
Rmsd from idealized
geometry
Bonds (A˚) 0.00114 ± 0.00003 0.00353 ± 0.00009
Angles () 0.278 ± 0.002 0.486 ± 0.010
Impr () 0.149 ± 0.007 1.518 ± 0.096
Coordinate precisionc
Backbone (all residues) 1.30 ± 0.27 1.36 ± 0.23
All heavy atoms (all
residues)
1.50 ± 0.20 1.54 ± 0.18
Backbone (structured
regions)
0.36 ± 0.05 0.46 ± 0.06
All heavy atoms
(structured regions)
0.74 ± 0.06 0.81 ± 0.06
Stereochemistryd
Ramachandran plot (%)
(all residues)
Percentage in most
favored regions
75.2 ± 3.0 77.2 ± 1.6
Percentage in additionally
allowed regions
23.7 ± 3.2 21.5 ± 1.7
Percentage in generously
allowed regions
0.8 ± 0.8 0.8 ± 0.7
Percentage in disallowed
regions
0.3 ± 0.6 0.6 ± 0.3
Ramachandran plot (%)
(structured regions)
Percentage in most
favored regions
82.6 ± 2.5 83.8 ± 2.0Structure 17, 1398–IL-33 and ST2 (Figure 3A). During the titration, resonances of the
unbound IL-33 disappear gradually and new signals emerge at
different locations in the spectrum. The binding is therefore in
the slow exchange regime on the NMR time scale, as expected
for a high-affinity interaction. The large degree of chemical shift
changes and the type of interaction did not allow us to easily
assign IL-33 in the complex by following the resonances of
IL-33 during the titration with ST2. We therefore performed a
completely new backbone assignment of IL-33 in complex with
ST2 using fully 2H/13C/15N-labeled IL-33. This enabled assign-
ment of 90% of the backbone resonances of IL-33 in complex
with ST2 and determination of chemical shift perturbations on a
per-residue basis (Figure 3B). Residues with the largest changes
form two clusters in the IL-33 fold, which are connected by resi-
dues that experience moderate changes (Figures 3B and 3C).
The first cluster comprises the solvent-exposed side of the
b2-b3 hairpin, with E34 showing a very large chemical shift
change, together with residues in the b10-b11 turn and residues
in the b3-b4 loop, which is highly charged (Figure 3C). Two cross
peaks (for K42 andD43) are too broad to assign, presumably due
to exchange. A second cluster is formed by residues at the
bottom of the b barrel, notably residues at the N termini of b1
and b5, in the b8-b9 turn (where the signals broaden due to bind-
ing), and the C terminus of b12. Both spatial clusters in IL-33
overlap with the IL-1R1-binding surface of IL-1b, conveying
a similarly positioned binding site for ST2. With an available
Table 1. Continued
hSAia hSAiwater refineda
Percentage in additionally
allowed regions
17.4 ± 2.5 16.1 ± 2.2
Percentage in generously
allowed regions
0 0.2 ± 0.4
Energies (kcal mol1)e
ENOE 7.5 ± 1.7 32. 2 ± 10
ECDIH 0.4 ± 0.1 2.9 ± 0.7
Ebond 3.3 ± 0.2 31.5 ± 1.6
Eangles 54.1 ± 0.8 165.0 ± 7.0
Eimpr 4.4 ± 0.4 458.5 ± 60
a hSAi is an ensemble of the ten lowest energy solution structures of IL-33
(out of 100 calculated). The CNS Erepel function was used to simulate
van der Waals interactions with an energy constant of 25.0 kcal mol1A˚4
using ‘‘PROLSQ’’ van derWaals radii. 1 kcal = 4.18 kJ. For hSAiwater refined,
the ensemble of hSAi structures was refined in a shell of water.
bHydrogen bonds were derived from slowly exchanging amide protons
and were applied as two distance restraints with bounds of 1.8–2.3 A˚
(H–O) and 2.8–3.3 A˚ (N–O).
cCoordinate precision is given as the Cartesian coordinate rmsd of the
ten lowest-energy structures in the NMR ensemble with respect to their
mean structure for the full-length IL-33 and the structured regions of
IL-33 (residues 10–39, 47–56, 71–142, and 151–158).
d Structural quality was analyzed using PROCHECK (Laskowski et al.,
1996) for full-length IL-33 and for the structured regions of IL-33 (residues
10–39, 47–56, 71–142, and 151–158).
eNOESY-derived distance restraints were used with a soft square-well
potential using an energy constant of 50 kcal mol1 A˚2. Dihedral angle
restraints were applied using an energy constant of 200 kcal mol1
rad2. The force constants were 1000 kcal mol1 A˚2 for bond length
and 500 kcal mol1 rad2 for angles and improper dihedrals.1410, October 14, 2009 ª2009 Elsevier Ltd All rights reserved 1401
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Heterotrimeric IL-1 Signaling ComplexesFigure 2. Binding of IL-33 to ST2 and IL-1RAcP
(A) Size exclusion chromatography analysis. (Left) Individual proteins were mixed and analyzed on a Superdex 200 10/300 GL column. The color of the individual
traces matches the labeled boxes, and numbers on peaks in the profiles correspond to lanes in the gel shown in (B). Protein molecular weights of a gel filtration
standard are indicated above the chromatograms.
(B) SDS-PAGE of the individual peaks of the size exclusion chromatography analysis shown in (A).
(C) Isothermal titration calorimetry binding curves. ST2 was titrated with IL-33 (left) and the IL-33/ST2 complex was titrated with IL-1RAcP (right). The binding
curves were fit with a 1:1 binding model, resulting in the deduced stoichiometry n and the thermodynamic parameters listed in the table.structure for the human ST2 ectodomain absent, a comparative
molecular model was built with MODELER (Sali and Blundell,
1993) based on the IL-1R1 template taken from the IL-1b/
IL-1R1 complex (PDB entry 1ITB). While the two receptor chains
have a sequence identity of only 23% (over 308 aligned resi-
dues), key disulfide bonds are preserved along with the D1-D2
repeat segment structure; in addition, model quality assessment
by VERIFY3D (quality score of 91.18 [Luthy et al., 1992]) is
consistent with a good ST2 ectodomain model. The concave
interaction surface of repeats D1-D2 is positively charged, com-
plementing the negatively charged first residue cluster identified
in IL-33 (Figure 3D). In contrast, the cytokine-facing surface of D3
is partly hydrophobic and partly electronegative, and therefore
represents a complementary binding site for the second cluster
region on IL-33.
The long b4-b5 loop, which is flexible in the free IL-33 (see
above), is close to cluster 2 and contains several residues1402 Structure 17, 1398–1410, October 14, 2009 ª2009 Elsevier Ltddisplaying chemical shift changes upon ST2 binding. Heteronu-
clear {1H}-15N NOE analysis of the complex reveals that this
region is less flexible when IL-33 is bound to ST2, but still has
NOE values lower than residues in regular secondary structure
(data not shown). Binding analysis shows that the b4-b5 loop is
dispensable for receptor interaction, as a mutated form of
IL-33 lacking this loop (residues H58 to V67 deleted) is still
capable of binding to ST2 with a similar affinity. This suggests
that most of the chemical shift changes in this region are due
to secondary binding effects.
In order to substantiate the predicted interface between IL-33
and ST2 and to search for possible ‘‘hot spot’’ residues of this
interaction, we introduced mutations based both on the amino
acid clusters defined by the chemical shift perturbation data
and on residue conservation between IL-33, IL-1b, and IL-18.
In total, 28mutationsweremade and all proteins were expressed
in E. coli and purified (Figure S3) for binding trials. In order toAll rights reserved
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Heterotrimeric IL-1 Signaling Complexesscreen quickly the large number of IL-33 variants for ST2 binding,
we used a binding assay based on biolayer interferometry
(Octet). Multiple independent screens revealed that only one of
our mutants (E34K) had a pronounced effect on the interaction
between IL-33 and ST2 (Figure S4). Surface plasmon resonance
(Biacore) analysis provided a more precise comparison for the
wild-type versus charge-reversal E34K IL-33 proteins in binding
ST2 (Figure S5), showing a reduction in affinity for the mutant by
7-fold from 0.45 nM to 3.11 nM. The absence of additional hot
spots implies that the binding energy for the interaction between
Figure 3. NMR Analysis of ST2 Binding to IL-33
(A) Chemical shift perturbation after addition of ST2 to 2H/13C/15N-labeled IL-33. Chemical shifts weremonitored in 1H, 15N TROSY correlation spectra at 800MHz
1H Larmor frequency. Slow exchange on the NMR chemical shift timescale between free and bound states indicates tight binding with nanomolar affinity.
(B) Bar diagram of chemical shift perturbations. Dd is the weighted chemical shift change of IL-33 backbone amides upon addition of ST2 (see Supplemental
Experimental Procedures). Gray squares indicate prolines and unassigned residues.
(C) Ribbon representation of the two binding regions, with surface coloring according to chemical shift change and electrostatic surfaces of IL-33. (Left) ribbon
representation of IL-33 in the same orientation as in the other panels. The views in the upper and lower panel are correlated by a 90 rotation around the x axis.
(Middle) Surface representation of IL-33with residues colored according to the chemical shift perturbation upon binding of ST2. Prolines and unassigned residues
are shown in gray. The two regions of major chemical shift changes are outlined by a dotted line and labeled. (Right) Surface representation of IL-33 colored by
electrostatic potential. White, blue, and red corresponds to neutral, positive, and negative electrostatic potential, respectively.
(D) Electrostatic surface and ribbon representation of the ST2model. Surface representation of the ST2model colored by electrostatic potential. A ribbon diagram
is shown in the same orientation with the individual Ig domains labeled.Structure 17, 1398–1410, October 14, 2009 ª2009 Elsevier Ltd All rights reserved 1403
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Heterotrimeric IL-1 Signaling ComplexesFigure 4. Model and SAXS Validation of the IL-33/ST2 Complex
(A) A model of the IL-33/ST2 complex was generated based on chemical shift perturbation data on IL-33 and homology to the IL-1b/IL-1R1 complex using the
molecular docking software HADDOCK. The surface of the ST2 receptor is shown in white, whereas the residues of IL-33 are colored according to the degree of
chemical shift change (same coloring scheme as in Figure 3C). The views are correlated by a 180 rotation around the y axis. The Ramachandran plot statistics are
shown on the right.
(B) SAXS analysis of the IL-33/ST2 complex. (Left) The experimental (black dots) and back-calculated scattering curves (red line) of the IL-33/ST2 complex
are shown and the scattering intensities are displayed as a function of the momentum transfer s. The fitting statistics are shown above the two curves. (Right)
The IL-33/ST2 model was placed into the ab initio SAXS envelope; two orientations related by a 90 rotation are shown. IL-33 is colored in green and ST2 in blue.IL-33 and ST2 is a sum of many small contributions spanning the
large contact site. In contrast, for both the IL-1b/IL-1R1 (Bora-
schi et al., 1995; Evans et al., 1995) and IL-18/IL-18Ra (Kato
et al., 2003; Kim et al., 2002; Krumm et al., 2008) interactions,
similar individual mutations had a larger effect on the binding
affinity.
Small-Angle X-Ray Scattering Analysis
of the IL-33/ST2 Complex
The chemical shift perturbation data suggest that the complex of
IL-33 and ST2 is architecturally very similar to the IL-1b/IL-1R1
complex. With this assumption, we used the program
HADDOCK (Dominguez et al., 2003) to construct a model of
the IL-33/ST2 complex. Restraints for interaction residues of
IL-33 were defined based on the chemical shift perturbation
data; residues in ST2 were chosen from the superposition of
the IL-33 structure and ST2 model with the respective cyto-
kine/receptor chains in the IL-1b/IL-1R1 complex. This latter
structure also served as a starting pose for the IL-33/ST2 rigid-
body docking step in HADDOCK. In the second docking step,
loop sequences in IL-33 and ST2were allowed to be fully flexible,
resulting in an energy-minimized model of the IL-33/ST2 com-
plex without steric clashes and with good stereochemistry
(Figure 4A). To obtain independent structural information on
the IL-33/ST2 complex, we performed small-angle X-ray scat-
tering (SAXS) analysis, which provides information about the1404 Structure 17, 1398–1410, October 14, 2009 ª2009 Elsevier Ltdsize and overall shape of macromolecules in solution (Putnam
et al., 2007; Svergun and Koch, 2002). The calculated scattering
curve of the IL-33/ST2model fits the experimental data well, with
a low c2 value of 1.69 (Figure 4B) and a value for the radius of
gyration (Rg) of the IL-33/ST2 complex derived from the experi-
mental scattering curve as 29.9 A˚, which is close to the back-
calculated Rg of our IL-33/ST2 model (27.8 A˚) using CRYSOL
(Svergun et al., 1995). The shape of the complex in solution
was also reconstructed from the experimental scattering curves
using GASBOR (Svergun et al., 2001). Fifteen independent
models were calculated and averaged using DAMAVER (Volkov
and Svergun, 2003). The envelope of the reconstructed shape
was superposed on the IL-33/ST2 model with SUBCOMB (Kozin
and Svergun, 2001), with a very good fit showing a low normal-
ized spatial discrepancy (NSD) of 0.88 (Figure 4B). Together,
this provides strong evidence that our model of the heterodi-
meric complex is very close to the structure adopted in solution.
Binding of IL-1RAcP to the IL-33/ST2 Complex Induces
Few Additional Chemical Shift Changes in IL-33
Having assigned the backbone resonances of IL-33 in the IL-33/
ST2 heterodimer, we asked next if the addition of IL-1RAcP to
create the ternary complex induces further resonance changes
in IL-33, which could be explained by a direct interaction be-
tween the cytokine and the coreceptor. To this effect, IL-1RAcP
was added in three steps to a purified complex of fullyAll rights reserved
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Heterotrimeric IL-1 Signaling ComplexesFigure 5. Binding of the Coreceptor Monitored by NMR
(A) Chemical shift perturbation after addition of IL-1RAcP to 2H/13C/15N-labeled IL-33 in complex with ST2. Chemical shifts were monitored in 1H, 15N TROSY
correlation spectra at 900MHz 1H Larmor frequency. Slow exchange on the NMR chemical shift time scale between free and bound states indicates tight binding
with submicromolar affinity.
(B) IL-33 residues are colored according to the different classes used to analyze chemical shift perturbations upon addition of the IL-1RAcP coreceptor to the
IL-33/ST2 complex (see text). The surface of ST2 is shown in blue.2H/13C/15N-labeled IL-33 and ST2, until a 1:1:1 molar ratio was
reached (Figure 5A). Similar to the interaction between IL-33
and ST2, we observed binding in the slow exchange regime on
the NMR time scale. Due to the increasing molecular weight of
the complex and the faster transverse relaxation, the peaks
experience additional broadening that results in a decrease of
intensity. Although most of the IL-33 resonances do not change
their position in the spectrum significantly, we observe some
chemical shift perturbation for a number of peaks. Because it
was not feasible to perform a new backbone assignment on
the ternary complex, we performed a careful comparison of
the TROSY spectra of the heterodimeric and ternary complexes
and grouped residues into four different classes based on their
assigned position in the heterodimeric complex: (1) no change,
peak is at the same position in the spectrum of the ternary
complex, (2) the peak position changed between half a line width
and one line width, (3) the peak position changed by R1 line
width, and (4) residues for which the peak position information
is missing. With this analysis, we found that addition of IL-1RAcP
to the IL-33/ST2 complex only causes additional chemical shift
perturbations of residues that are proximal to the interface
between IL-33 and ST2 (Figure 5B). Strikingly, there were no
changes observed for residues facing the solvent-exposed
side of IL-33, showing that the coreceptor is not binding to this
surface area.
As additional experiments that would probe the spatial posi-
tioning of the coreceptor chain in the ternary complex, two
IL-33 variants were produced to further test the binding of both
ST2 and IL-1RAcP. The first variant was an IL-33 C-terminal
fusion (with a short Gly-Ser linker) to mannose-binding protein
(MBP) and the second an insertion of green fluorescent protein
into the b11-b12 loop of IL-33. Both IL-33 variants retain binding
to both ST2 and IL-1RAcP, in spite of the large masses that
‘‘balloon’’ out to the ‘‘right’’ (MBP) and ‘‘left’’ (green fluorescentStructure 17, 1398–protein) sides of the disk-like IL-33/ST2 complex (Figure S6).
A recent finding that pro-IL-33 is active and can bind to both of
its receptors (Lamkanfi and Dixit, 2009) is consistent with our
results, since the 111 residue prodomain would be fused to the
N-terminal residue of IL-33, spatially close to the C-terminal
MBP fusion.
Structural Characterization of IL-1/IL-1 Receptor
Holocomplexes by Small-Angle X-Ray Scattering
As there are no structural data available for the heterotrimeric
complexes IL-1-like cytokines form with their respective recep-
tors and coreceptors, we performed additional SAXS experi-
ments on the homologous IL-1b/IL-1R1/IL-1RAcP and IL-33/
ST2/IL-1RAcP complexes. Since IL-1RAcP is the common co-
receptor chain for both IL-1b and IL-33 cytokines, a similar spatial
engagement is expected for both ternary complexes. Analysis of
the scattering curves of the IL-1b- and IL-33-containing hetero-
trimers resulted in very similar Rg values of 35.8 A˚ and 37.3 A˚ for
the IL-1b/IL-1R1/IL-1RAcP and IL-33/ST2/IL-1RAcP complexes,
respectively. Furthermore, the ab initio reconstruction-derived
SAXS envelopes look globally similar with a NSD of 0.64 (Fig-
ure S7). Thus, the IL-1 cytokine and its two receptor chains
seem to adopt an equivalent and conserved arrangement with
a curved kidney-like shape.
To reveal the position of the individual proteins in the trimeric
complexes, we applied the unbiased approach of preparing
possible models of the holocomplexes and testing which of
them best reflects the experimental scattering curve. As building
block components of the respective complexes, we took the
crystal structure of the IL-1b/IL-1R1 complex and the calculated
model of the IL-33/ST2 complex, together with the common
subunit, a homology model of the coreceptor (also built on the
IL-1R1 template). The IL-1RAcP ectodomain features the
family-distinctive set of three Ig repeats. D1 andD2 are very likely1410, October 14, 2009 ª2009 Elsevier Ltd All rights reserved 1405
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Heterotrimeric IL-1 Signaling ComplexesFigure 6. Characterization of the IL-1b/IL-1R1/IL-1RAcP and IL-33/ST2/IL-1RAcP Complexes by SAXS Analysis
(A) SAXS data from the IL-1b/IL-1R1/IL-1RAcP complex. (Left) The experimental scattering curve is shown with black dots, the scattering profile of the IL-1b/
IL-1R1/IL-1RAcP model is shown as a red line. The fitting statistics are shown above the two curves. (Right) The IL-1b/IL-1R1/IL-1RAcP model was placed
into the ab initio SAXS envelope; two orientations related by a 90 rotation are shown. IL-1b is colored in green, IL-1R1 in blue, and IL-1RAcP in red.
(B) SAXS data from the IL-33/ST2/IL-1RAcP complex. (Left) The experimental scattering curve is shown with black dots, the scattering profile of the IL-33/ST2/
IL-1RAcPmodel is shown as a red line. The fitting statistics are shown above the two curves. (Right) The IL-33/ST2/IL-1RAcPmodel was placed into the ab initio
SAXS envelope; two orientations related by a 90 rotation are shown. IL-33 is colored in green, ST2 in blue, and IL-1RAcP in red.interacting closely with each other as in IL-1R1 and ST2 because
of the conserved register of Cys residues; likewise, a flexible
linker of seven amino acids links domain D3 to the D1-D2
segment. Given the reasonable assumption that the linker can
adopt a wide range of conformations, we independently posi-
tioned the Ig repeat segments D1-D2 and D3 within a distance
that can be bridged by the linker (25 A˚). Although this proce-
dure introduces an additional degree of uncertainty to our model
building approach, it allows us to account for the expected plas-
ticity of the linker.
All models in which the coreceptor binds over the solvent-
exposed surface of the cytokine did not correspond to the exper-
imental scattering curves, resulting in very high c2 values
(Figures S8A and S8B). This agrees well with the observation
that residues of the solvent-exposed surface of IL-33 did not
experience any chemical shift perturbations when we added
IL-1RAcP to the IL-33/ST2 heterocomplex. We can thus rule
out any arrangement of the trimeric complexes that involves
binding of the coreceptor from the front. Even higher c2 values
were observed for models wrapping IL-1RAcP on the reverse
side of the dimeric complexes in a diagonal fashion, as previ-
ously proposed in the back model of Casadio et al. (2001)
(Figures S8C and S8D). A lower c2 value is observed for a model
that has the coreceptor mounted completely on the convex1406 Structure 17, 1398–1410, October 14, 2009 ª2009 Elsevier Ltdspine of the primary receptor in parallel (Figure S8E), supporting
the notion that the trimeric complex has a much thinner profile
than the front or the back models. However, the c2 value of
this arrangement is still above a value that gives confidence
that the model is optimally representing the particle in solution.
Therefore, we also investigated models that place the corecep-
tor in parallel next to the primary receptor on either side (akin to
the FGFR homodimer stance [Mohammadi et al., 2005], which
resulted in slightly worse statistics [Figures S9A and S9B]). We
could improve the agreement between the back-calculated
scattering curves and the experimental curves by moving the
IL-1RAcP chain upwards when the coreceptor is placed on the
right side of the dimeric complex seen from the front. This
resulted in low c2 values of 1.65 and 2.19 for the IL-1b/IL-1R1/
IL-1RAcP and IL-33/ST2/IL-1RAcP complexes, respectively
(Figures 6A and 6B). Furthermore, the complexes fit well into
the reconstructed shapes with NSDs of 1.10 and 1.12. In these
models, the D3 module of IL-1RAcP is packed close to the D3
domains of ST2 or IL-1R1, bringing the two C termini of the
signaling receptor chains into proximity. The D1-D2 segment
of the coreceptor is placed close to the top-mounted D1 domain
of the primary receptor in such a fashion that the D2 domain of
IL-1RAcP interacts with the D1 module and the D1-D2 interface
of ST2 and IL-1R1. In our models, the flexible linker between theAll rights reserved
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Heterotrimeric IL-1 Signaling Complexesseparated D1-D2 and D3 IL-1RAcP domains bridges 24.9 and
22.3 A˚ distances, respectively, in the IL-1b and IL-33 ternary
complexes.
DISCUSSION
The modular architecture of IL-1 receptors places them at the
evolutionary crossroads of two ancient structural superfamilies,
with a triple Ig repeat ectodomain that recognizes b-trefoil class
cytokines, an interaction conserved between IL-1 and FGF cyto-
kine/receptor families (Ponting and Russell, 2000; Vigers et al.,
1997), and a cytosolic TIR domain shared with Toll-like receptors
(TLRs) that links the respective molecules to a common NF-kB
signaling pathway (O’Neill, 2008). However, FGFRs differently
harness cytokine binding to dimerization of a cytosolic tyrosine
kinase domain, while pathogen recognition drives the assembly
of distinctive Leu-rich repeat TLR ectodomains to trigger intra-
cellular TIR signaling (Jin and Lee, 2008; Mohammadi et al.,
2005). Modular diversity aside, these structurally interlinked
families of receptors share a common functional imperative:
cytokine binding (or pathogen recognition, in the case of TLRs)
drives the oligomerization of receptor chains into a ternary
complex that critically bundles together transmembrane helices
and cytosolic signaling domains. The attendant cytokine recog-
nition and assembly mechanisms of IL-1 receptors were only
partly disclosed by the structure of the IL-1b/IL-1R1 heterodimer
complex (Vigers et al., 1997), which further left open the inviting
prospect of a face-to-face (or pseudosymmetric) docking of the
unseen IL-1RAcP coreceptor chain. This front bindingmodel has
been questioned by Casadio et al. (2001), who suggested that
the IL-1RAcP coreceptor adopts an alternative and unorthodox
orientation in the ternary complex. The present work strives to
answer this outstanding question by applying NMR-based
structural, biochemical, and SAXS methods to show how IL-33
interacts with both its primary receptor ST2 and coreceptor
IL-1RAcP; we further extend our studies to the homologous
IL-1b cytokine/receptor complex.
The solution structure of human IL-33 shows that this distant
member of the IL-1 family adopts a b-trefoil fold similar to that
of the other IL-1 cytokines, but with a unique insert of approxi-
mately ten residues in the b4-b5 loop. This insert is flexible in
solution and is not required for folding or solubility. IL-33 binds
its primary receptor ST2 in solution with high affinity, a 1:1 stoi-
chiometry, and an extensive buried surface area of contact. As
deduced from chemical shift binding data, the interaction site
in IL-33 comprises two separated contact regions: region 1
includes mainly strand b3 and the b1-b2 and b3-b4 loops. E34
in b3 provides a large contribution to the binding energy, as a
charge-reversal mutation decreases the affinity by approxi-
mately 7-fold; region 2 is otherwise located at the base of the
b barrel. Drawing from the crystal structure of the IL-1b/IL-1R1
complex, IL-1b is likewise shown to have two detached binding
sites for IL-1R1: the one referred to as site A nestles against the
D1-D2 Ig-repeat segment whereas the other, site B, contacts D3
(Vigers et al., 1997). The interaction mode between cytokines
and their cognate receptors tends to be strongly conserved in
families despite great sequence divergence (Stroud and Wells,
2004), so we expect that the IL-1b/IL-1R1 binding mode is
preserved in the interaction of IL-33 with its primary receptor,Structure 17, 1398–where region 1 of IL-33 would bind the ST2 D1-D2 segment
and region 2 would engage D3. Our model of the IL-33/ST2
complex based on the chemical shift perturbation data and
homology to the IL-1b/IL-1R1 complex supports these predic-
tions. Furthermore, the solution scattering curve of the IL-33/
ST2 complex validates our model, which fits also very well into
the SAXS-derived shape reconstruction. This result represents
the first structural demonstration of the architecture of IL-1-like
cytokines bound to their primary receptor in solution.
Using purified recombinant proteins, we have shown that
IL-1RAcP binds to the complex of IL-33 and ST2with a 1:1:1 stoi-
chiometry, forming a stable heterotrimeric assembly. Casadio
et al. (2001) showed that an antibody directed against residues
in the b6-b7 turn and strand b7 of IL-1b (residues 73–81) did not
inhibit the biological effect of IL-1b in cell-based assays, thus dis-
favoring their computationally-derived front model for the inter-
action of IL-1RAcP with the IL-1b/IL-1R1 complex (Casadio
et al., 2001). A similar conclusion can be drawn from a study
showing that mutations in the residue 74–80 area did not affect
the biological activity of IL-1b (Simon et al., 1993). In contrast,
an antibody directed against the b5-b6 turn and strand b6 of
IL-1b (residues 61–70) inhibited IL-1b-directed signaling without
interfering with IL-1R1 binding (Casadio et al., 2001; D’Ettorre
et al., 1997). In a study that attempted to map the binding site
for IL-1b/IL-1R1 on IL-1RAcP using antibodies raised against
various Ig repeat-derived coreceptor peptides, Yoon and Dinar-
ello (1998) reported data suggesting that repeats D2 and D3 of
IL-1RAcP are primarily involved in the interaction with IL-1b/
IL-1R1. In addition, the juxtamembrane module D3 of the
coreceptor appeared important for proper dimerization of the
intracellular chains of IL-1R1 and IL-1RAcP, which is required for
activation. Interestingly, the IL-1b antagonist, IL-1Ra, engages
the D1-D2 segment of IL-1R1 almost exclusively (with a binding
surface corresponding to our site A), whereas few contacts are
maintained with D3, which appears rotated away by 20 in the
IL-1Ra/IL-1R1 complex compared to the IL-1b/IL-1R1 structure
(Schreuder et al., 1997). Furthermore, the IL-1Ra/IL-1R1 hetero-
dimer does not bind the coreceptor chain, suggesting that
the area of greatest structural divergence with the agonist IL-1b
complex—the vicinity of the cytokine-disengaged D3 domain—
might be involved in the loss of recognition of IL-1RAcP.
Our NMR-based study of the interaction of the IL-33/ST2
complex with IL-1RAcP and the SAXS analysis of the IL-1b
and IL-33 holocomplexes clearly rule out any ternary arrange-
ment that places the coreceptor on the open, cytokine-exposed
front face of the heterodimeric complexes. However, our SAXS
data are also clearly incompatible with back models where the
coreceptor wraps across the convex spine of the primary
receptor, and instead we provide evidence that both IL-1b and
IL-33 holocomplexes feature a similar and conserved binding
mode of IL-1RAcP to the right side of both complexes. The
proposed models reveal a novel architecture of IL-1-type
b-trefoil cytokine signaling complexes. Receptor-ligand com-
plexes formed by the FGF b-trefoil cytokines minimally comprise
two FGF molecules and two identical FGFR chains in a 2:2 stoi-
chiometry, with symmetrically placed heterocomplexes bridged
by a heparin strand (Figure 7B) (Mohammadi et al., 2005). Only
FGFR Ig repeats D2 and D3 are needed to bind cytokine, and
furthermore, the receptor homodimer contact ismediatedmainly1410, October 14, 2009 ª2009 Elsevier Ltd All rights reserved 1407
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a 1:1 stoichiometry and therefore need to recruit a second and
distinct coreceptor chain to form the bioactive 1:1:1 heterotri-
meric complex. This staged assembly resembles the strategy
Figure 7. Cartoons Comparing the Formation of Active Signaling
Complexes for IL-1, FGF, and Helical Cytokines
(A) The IL-33 system is shown as a representative for the IL-1 cytokine family.
IL-33 (green) is binding to the ST2 receptor (blue): complex formation enables
the recruitment of the coreceptor IL-1RAcP (red). In the ternary 1:1:1 complex,
the two cytoplasmic TIR domains (yellow) are proximal, resulting in activation
of the signaling cascade.
(B) In contrast, FGF cytokines (green) bind to FGFR (blue), forming a 2:2
complex in the presence of heparin (red). The proximity of the intracellular tyro-
sine kinase domains (orange) leads to activation.
(C) In the helical cytokine system, the ternary signaling complex also consists
of the cytokine and a pair of receptors (primary Ra and secondary Rb). This
can be a homodimeric pair of receptor chains in the case of growth hormones
or a heterodimeric pair of receptor chains as seen for the short chain helical
cytokines like IL-2, IL-4/13, or GMCSF. Activation is achieved by clustering
of intracellular chains bearing JAK family kinases bound to conserved, juxta-
membrane Box1-2 motifs.1408 Structure 17, 1398–1410, October 14, 2009 ª2009 Elsevier Ltdof helical cytokine complexes, with important architectural differ-
ences: four helix bundle cytokines bind in the heart of the
complex between two different receptor chains (Figure 7C)
(Wang et al., 2009). Surprisingly, the assembly of IL-1 receptors
is not centered around the ligand in a pseudosymmetric fashion
and is thus counter to most other cytokine systems. In our
present model, the IL-1RAcP coreceptor interacts mainly with
Ig repeats D1 and D3 of the primary receptor (ST2 in the case
of IL-33, IL-1R1 for IL-1b) and makes minor contacts with the
bound cytokine, principally along the seam of its binding inter-
face with the primary receptor (Figure 7A). Since we cannot
measure any interaction in solution between IL-1RAcP and either
cytokine or primary receptor alone, the docking surface for
coreceptor on the engaged IL-33/ST2 or IL-1b/IL-1R1 hetero-
dimers must only be present in the bound configuration. Taken
together, our models of the IL-33 and IL-1b holocomplexes
derived from a combination of NMR structural and binding anal-
ysis and low-resolution SAXS data are consistent with the
majority of experimental data available so far and advance
a novel mode of cytokine-receptor ternary association. Our
structural model of the IL-33 receptor signaling complex has
broad mechanistic implications for the larger IL-1 cytokine/
receptor family, as the close architectural resemblance to the
IL-1b complex attests, but in particular it should facilitate the
design and targeting of therapeutics that specifically (positively
or negatively) regulate the IL-33 signal.
EXPERIMENTAL PROCEDURES
Protein Preparation
Human IL-33 and IL-1b were expressed in E. coli as an N-terminal His tag
fusion protein and as a fusion protein with an N-terminal His-tagged
maltose-binding protein, respectively. For uniform 15N and 15N/13C labeling,
cells were grown in M9 minimal medium supplemented with 15NH4Cl without
or with 13C6-glucose. For the preparation of
2H/13C/15N-labeled sample, the
cells were grown in minimal medium prepared with 100% D2O and supple-
mented with 15NH4Cl and
2H/13C-rich glucose. His-tagged fusion proteins
were affinity purified, followed by protease cleavage. After removing the
tags, final purification was by gel filtration.
The extracellular domains of ST2, IL-1RAcP, and IL-1R1 were secreted from
insect cells as His tag fusion proteins. Supernatants were subjected to affinity
purification, the eluted fusion proteins protease cleaved and further purified by
size exclusion chromatography.
For SAXS measurements, the insect cell-secreted receptors were deglyco-
sylated using a mixture of four different enzymes: F1, F2, F3, and Endo H (all
QA-Bio).
NMR Spectroscopy
NMR spectra of IL-33 were analyzed using the CCPN analysis software
(Vranken et al., 2005). 1H, 13C, and 15N chemical shifts and sets of distance
and dihedral restraints were determined by standard methods. Slowly
exchanging amide protons were identified from 1H, 15N correlation experi-
ments after redissolving lyophilized protein in D2O.
Heteronuclear {1H}-15N NOE was measured on a 15N-labeled IL-33 sample
at 35C and 800 MHz 1H Larmor frequency and analyzed with the CCPN anal-
ysis software.
The IL-33/ST2 complex for analysis by NMR spectroscopy was formed by
titrating the 2H/13C/15N-labeled IL-33 with ST2 protein until a molar stoichiom-
etry of 1:1.2 was reached. For backbone assignments of the complex, TROSY
versions of backbone experimentswere used. The ternary complex comprised
of IL-33, ST2, and IL-1RAcP was prepared by adding IL-1RAcP to purified
IL-33/ST2 complex, in which IL-33 was 2H/13C/15N labeled. Changes were
observed by TROSY 1H, 15N correlation spectra.All rights reserved
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The experimentally determined distance and dihedral restraints for IL-33 (see
Table 1) were applied in a simulated annealing protocol using ARIA2.2 (Rieping
et al., 2007) and CNS (Brunger et al., 1998). The final ensemble of NMR struc-
tures was refined in a shell of water molecules (Linge et al., 2003). Structural
quality was analyzed using PROCHECK (Laskowski et al., 1996). Ribbon and
surface representations were prepared with PyMOL (DeLano Scientific).
Isothermal Titration Calorimetry
Proteins were dialyzed in 50mM sodium phosphate (pH 6.5) and 150mMNaCl
and afterwards measured using a VTC calorimeter (Microcal) at 30C. For the
analysis of the interaction between IL-33 and ST2, the sample cell was loaded
with 2.5 mMST2 and IL-33 was added over 20 injections of 5 ml of a 50 mMsolu-
tion. Interaction of the IL-33/ST2 complex with IL-1RAcP was measured using
5 mMof the purified complex in the sample cell and injecting 203 5 ml of 75 mM
IL-1RAcP.
Octet and Biacore Analysis
Protein-protein interactions were measured by biolayer interferometry using
the Octet QK system (ForteBio). Streptavidin biosensors were loaded with
10 mg/mL biotinylated ST2, followed by an association of IL-33 at 20 nM
concentration and a dissociation phase in the absence of IL-33.
For all Biacore experiments, the running and dilution buffer was HBS-EP.
A CM5 chip was coated with 7000 RU of anti-human IgG Fc antibody per
flow cell using amine coupling chemistry. An ST2-Fc fusion protein (R&D
Systems) was then immobilized on the surface of one of the flow cells and
a control-Fc fusion protein in the other flow cell. IL-33 was injected at different
concentrations and association/dissociation phases were obtained by sub-
tracting the signal of the control flow cell.
Small-Angle X-Ray Scattering Experiments
The SAXS data were collected at the beamline 4-2 of the Stanford Synchrotron
Radiation Lightsource (Smolsky et al., 2007). Sample-to-detector distances
of 0.5 m and 2.5 m were used to cover the Q range 0.01–0.3 A˚1 (Q is the
momentum transfer 4p sin(q/2)/l, with q and l being the scattering angle
and X-ray wavelength, respectively). Details of the SAXS data analysis are
included in the Supplemental Experimental Procedures.
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